A new study suggests that people with Alzheimer’s on the drug risperidone, an antipsychotic drug often prescribed as the brand name Risperdal, may be better off continuing to take the drug if they have not experienced negative side effects.
Because of the potential side effects, risperidone is only recommended to be prescribed for three to six months. After that point, a written explanation is required to continue the drug. A study, published in the New England Journal of Medicine and funded by the National Institutes of Health, investigated the effects of discontinuing the medication among individuals who had seen improvements as a result of the drug. Researchers prescribed risperidone to individuals with Alzheimer’s disease who showed signs of agitation and aggression. After 16 weeks, researchers put half of the individuals who did well on the drug on a placebo. The other half continued the treatment. The study found that those on the placebo were twice as likely to have their symptoms return. The rate of side effects and death were equal among the two groups.
Researchers warned that antipsychotics can carry the risk of serious side effects and should not be used on all individuals with Alzheimer’s disease, but discontinuing medication that has achieved benefits is not always the right choice. "One must be cautious about discontinuing the medication,” said study author Dr. D.P. Devanand, director of the division of geriatric psychiatry at Columbia Psychiatry and the New York State Psychiatric Institute in New York City. “If a person does well on it and there are not too many side effects, maybe they should stay on it for a while and be monitored closely."
For more information, read the article: Some With Alzheimer's Better Off Staying on Antipsychotics: Study Or, read the full study: Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease.
cheatsheet, Consumer Intelligence, Disabilities, End of Life, Facts and Figures, Health and Wellness, Managed Risk, Reports
The future of disability among older American adults will be affected by how the United States prepares for and manages a complex array of fiscal, med...
Allied Member, Best of the Best Awards, Business, CEO, cheatsheet, Clinical Quality and Quality Care Delivery, Community Awareness and Education, Community Leadership, Engage, Hero Awards, Human Resources, Marketing Strategy, Membership, Provider Member
ALFA’s annual awards program is now open for nominations, but the window is closing fast. Please consider nominating your most innovative people, proc...
Accessiblity Issues, Disabilities, Falls Prevention, Science and Technology
A new robot research project hopes to provide a solution for people who have limited hand functionality and who rely on wheelchairs for mobility. Rese...
cheatsheet, Health and Wellness, Managed Risk
The Centers for Disease Control and Prevention has released a long-term care toolkit with resources for senior living communities to provide access to...
Health and Wellness, Managed Risk
The Centers for Disease Control and Prevention has issued an official health advisory due to the high frequency in the United States of the H3N2 virus...
Most people with dementia never have screening, according to a new study published in the online issue of Neurology. “These results suggest that appro...
Family Relations, Health and Wellness, Memory Care Best Practices and Research, Memory Care Education
The National Institute on Aging offers holiday hints for caregivers of those who have Alzheimer’s disease. The tip sheet is available as an eBook and ...
It’s now open season for people seeking to switch health coverage plans and that means watch out for scams, says the Federal Trade Commission. The ...
Business Planning, Health and Wellness, Memory Care Best Practices and Research, Memory Care Education, Partnerships, Strategy
Senior living residents are encouraging providers to put increasing emphasis on brain health initiatives, according to Senior Living Executive. Senior...
End of Life, Managed Risk
The discussion about planning for end-of-life care or care for advanced illness is regaining traction among the health policy community and the public...